Gan & Lee's Insulin, Bofanglutide Success

Gan & Lee Pharmaceuticals announced positive clinical trial results for two of its key pipeline products: Insulin ludefen and Bofanglutide injection. Insulin ludefen, an ultra-long-acting once-weekly basal insulin analog, met its primary endpoint in the SUPER-3 Phase III clinical trial in China for type 2 diabetes, demonstrating superior HbA1c reduction compared to once-daily Insulin glargine U100. The drug also showed a favorable safety profile with no severe hypoglycemic events. Separately, Bofanglutide injection met its primary endpoints in the GRADUAL-1 Phase III clinical study in China for overweight and obesity, achieving significant body weight reductions and improvements in cardiovascular and metabolic parameters. Additionally, a Phase II clinical trial for Bofanglutide injection in the United States also met its primary endpoint, showing substantial weight loss in participants without type 2 diabetes. These results position Gan & Lee Pharmaceuticals as a strong contender in the metabolic disease treatment market.